Who signed the compensation letter agreement for NovoCure related to the Chief Medical Officer role?

The letter agreement was signed on behalf of Novocure GmbH by Frank Leonard and was also signed by Uri Weinberg. Both signatures are dated April 8, 2026, confirming acceptance of the Chief Medical Officer assignment and its compensation terms.

NovoCure (NASDAQ: NVCR) boosts pay as Uri Weinberg assumes CMO duties

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

NovoCure Limited reported a change to executive compensation as Uri Weinberg, M.D., Ph.D. takes on the additional role of Chief Medical Officer while continuing as Chief Innovation Officer. Under a letter agreement dated April 7, 2026, he will receive a stipend increasing his salary by CHF 5,000 per month for as long as he serves as Chief Medical Officer. The company states this additional amount is tied solely to the extra assignment and will not be included when calculating his annual incentive payment, while all other employment terms remain unchanged.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Monthly stipend increase: CHF 5,000 per month Exhibit 10.1: Weinberg Letter Agreement

2 metrics

Monthly stipend increase CHF 5,000 per month Additional compensation while serving as Chief Medical Officer

Exhibit 10.1 Weinberg Letter Agreement Sets out terms of CMO assignment and stipend

Key Terms

named executive officer, Chief Medical Officer, annual incentive payment (AIP), Inline XBRL

4 terms

named executive officer financial

"a named executive officer of the Company, in connection with his appointment"

Chief Medical Officer financial

"assume the role of Chief Medical Officer while concurrently performing your responsibilities"

A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.

annual incentive payment (AIP) financial

"this additional amount will not be included when calculating your annual incentive payment (AIP)"

Inline XBRL technical

"Cover Page Interactive Data File (embedded within the Inline XBRL document)"

Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

Understanding 8-K Material Events →

04/09/2026 - 05:04 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

April 8, 2026

Date of Report (date of earliest event reported)

NovoCure Limited

(Exact name of registrant as specified in its charter)


Jersey	001-37565		98-1057807
(State or other jurisdiction of incorporation or organization)	(Commission File Number)		(I.R.S. Employer Identification No.)

No. 4 The Forum, Grenville Street	St. Helier	Jersey	JE2 4UF
(Address of Principal Executive Offices)			(Zip Code)

+44 (0) 15 3475 6700

Registrant's telephone number, including area code

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Ordinary Shares, no par value	NVCR	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e) Amendment to Compensatory Arrangement with Named Executive Officer

On April 8, 2026, NovoCure Limited (the "Company"), through one of its affiliates, modified the compensation of Uri Weinberg, M.D., Ph.D., a named executive officer of the Company, in connection with his appointment as Chief Medical Officer in addition to his role as Chief Innovation Officer of the Company. Dr. Weinberg executed a letter agreement with the affiliate (the "Weinberg Letter Agreement") dated April 7, 2026, which provides that his salary is increased by CHF 5,000 per month so long as he remains in the role of Chief Medical Officer. The foregoing description of the Weinberg Letter Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Weinberg Letter Agreement, a copy of which is attached to this report as Exhibit 10.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.			Description

10.1			Weinberg Letter Agreement
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NovoCure Limited

(Registrant)

Date: April 9, 2026

By: /s/ Christoph Brackmann

Name: Christoph Brackman

Title: Chief Financial Officer

Exhibit 10.1

April 7, 2026

Uri Weinberg

6340 Baar, Zug Switzerland

Subject: Chief Medical Officer Assignment

Dear Uri,

On behalf of Novocure GmbH, we would like to thank you for your willingness to assume the role of Chief Medical Officer while concurrently performing your responsibilities as Chief Innovation Officer. Your readiness to take on this expanded scope of leadership reflects your strong commitment to the company and its mission.

In recognition of the additional responsibilities associated with this additional assignment, you will receive a monthly stipend of CHF 5,000 per month (gross) for the duration of the assignment. This increase is solely connected to the additional assignment. For avoidance of doubt, this additional amount will not be included when calculating your annual incentive payment (AIP). All other terms and conditions of your employment remain unchanged.

Acknowledgment

Please sign below to confirm your acceptance of the Chief Medical Officer assignment and the compensation terms outlined above.

Sincerely,

Novocure GmbH

/s/ Frank Leonard 8 April 2026
Frank Leonard Date

/s/ Uri Weinberg 8 April 2026
Uri Weinberg Date

Source: View Original Filing on SEC EDGAR

FAQ

What executive change did NovoCure (NVCR) disclose in this 8-K?

NovoCure disclosed that Uri Weinberg, M.D., Ph.D. has assumed the additional role of Chief Medical Officer while continuing as Chief Innovation Officer. The filing focuses on how his compensation is being adjusted to reflect these expanded responsibilities.

How is Uri Weinberg’s compensation changing at NovoCure (NVCR)?

His compensation includes a new stipend of CHF 5,000 per month for the duration of his Chief Medical Officer assignment. This amount recognizes the added responsibilities and is paid on top of his existing compensation package with the company.

Is the new CHF 5,000 monthly stipend included in NovoCure’s annual incentive payment (AIP) calculation?

No, the letter agreement states the CHF 5,000 monthly stipend will not be included when calculating Uri Weinberg’s annual incentive payment. It is described as solely connected to his additional Chief Medical Officer assignment at NovoCure GmbH.

Does the 8-K indicate other changes to Uri Weinberg’s employment terms at NovoCure (NVCR)?

The agreement specifies that all other terms and conditions of Uri Weinberg’s employment remain unchanged. Only the additional monthly stipend for his Chief Medical Officer assignment is modified, leaving his broader employment arrangements intact.

What is the nature of the Weinberg Letter Agreement attached as Exhibit 10.1?

The Weinberg Letter Agreement is an executive compensation letter detailing Uri Weinberg’s assignment as Chief Medical Officer and the related CHF 5,000 monthly stipend. It is incorporated as Exhibit 10.1 and is referenced as the full legal source of the amended terms.

Filing Exhibits & Attachments

4 documents

Press Releases

EX-99.1 EX-99.1 5.6 KB